Episode # 6
The Alzheimer's Solution Revolution
#6— How Early in Life Can You Begin to Assess AND Track Your Risk for Late-Onset Alzheimer’s Disease?
Read More
EPISODE 5
Summary and Audio
Welcome, everyone!
This is Ralph Sanchez, and I am so pleased to bring you episode #6 to you here at the Alzheimer’s Solution Revolution Channel.
I am very much looking forward to today’s topic, which is centered on the assessment of risk biomarkers for late-onset Alzheimer’s disease.
I’ll begin this overview with a question.
Has your physician ever advised you on the possibility that you might be at an increased risk for dementia or late-onset Alzheimer’s disease (LOAD)?
And in the regard, just how early in life is it prudent to begin the process of a personalized risk evaluation?
In fact, there has been a significant shift in the medical and research community mindset over the last 10 years, and the consensus is that midlife, or earlier, is a critical window of time to begin doing so.
Why?
Because by midlife the brain damage associated with LOAD which begins earlier in life, begins to hit a pivotal tipping point in terms of your risk for LOAD—particularly if you are more susceptible to the disease.
Thus, midlife potentially is a critical juncture that shapes what your cognitive health future and life will look like.
Now, I’ve talked about this in my book, articles, newsletters, and social media posts many times as Alzheimer’s disease has a lengthy time frame of development and progression.
Indeed, the prevailing wisdom over these last few years has been finally emerged that the course of LOAD has a timeline of 20 to 30 years or so in which the disease process progresses.
And bear in mind, LOAD is a silent disorder in the asymptomatic stage—the preclinical stage, which often has its roots in cardiometabolic disease (type 2 diabetes/cardiovascular disease).
So today, I’ll be giving you some vital information on recent research findings that showcases what I just covered regarding your potential risk for LOAD, and how you can manage your healthy aging and reduce your risk for dementia through the assessment of biomarkers.
Case in point, the findings of a recently published study—an offspring study of the Framingham Heart Study, revealed that: “These findings show for the first time that cardiovascular risk factors, including HDL which has not been consistently reported as a strong risk factor in Alzheimer’s disease, contribute to the risk of Alzheimer’s disease starting as early as age 35.”
Undoubtedly, if you have a family history of cardiometabolic disease, or dementia, it is critical to start looking at these risk factors earlier in life.
The pathology linked to the late-onset Alzheimer’s disease continuum and vascular dementia spans decades, and it can be arrested or reversed in the early stages of the disease process.
Think ahead, and lease listen to the podcast to get the rest of the story!
Ralph Sanchez, MTCM, CNS, D.Hom.
BrainDefend®
https://www.TheAlzheimersSolution.com
https://www.facebook.com/TheAlzheimersSolution/
Top Takeaways
• The assessment of risk biomarkers for late-onset Alzheimer’s disease (LOAD) is best leveraged early in life for determining an optimal and personalized intervention program.
• Biomarkers that can be tracked via blood chemistry assessments and many other functional health evaluations can provide invaluable insights into metabolic dysfunction, immune system health, chronic inflammation patterns, gut and microbiome health, and hormone imbalances, enable priceless insights regarding risk factors associated with an increased risk for LOAD.
• A recent sub-study of The Framingham Heart study has shown that cardiovascular risk biomarkers may contribute to the risk for LOAD starting as early as age 35.
• The onset of cognitive impairment in the aging process is strongly associated with cardiovascular disease and type 2 diabetes which also increases the risk for stroke (traumatic brain injury). These major age-related disease of our time are modifiable which underscores the importance of early assessments and interventions.
• Genetic risk variants, such as the ApoE4 variant, can provide invaluable insights into the risk for both cardiovascular and late-onset Alzheimer’s disease.
Epidsode 6
Timestamp Highlights
In this Episode
[00:59] How early in life is it wise to begin the process in the risk assessment for late-onset Alzheimer’s (LOAD) disease?
[3:03] In my book, “The Diabetic Brain in Alzheimer’s Disease”, I reinforce the importance of risk assessments associated with cardiovascular disease and type 2 diabetes as both disease processes (cardiometabolic disease) significantly raises your risk for LOAD as you age.
[4:15] What are biomarkers, and what can they be useful for in tracking your health and the risks for certain diseases?
[7:02] Why the evaluation of optimal or “functional” labs measurement ranges of biomarkers are invaluable in a prevention-minded approach to preventing age-related diseases.
[11:20] REWIND trial report and quote on finding: “Cognitive impairment predicted risk for major cardiovascular events, stroke, and death in patients with type 2 diabetes”—cart before the horse?
[14:10] Report on the findings of a Framingham Heart sub-study (2017) that found a significant association between an increase of blood glucose levels and the risk for Alzheimer’s disease.
[17:18] Dr. Zhang quote from Framingham Heart sub-study (Offspring Study-1971) findings : “These findings show for the first time that cardiovascular risk factors, including HDL which has not been consistently reported as a strong risk factor in Alzheimer’s disease, contribute to the risk of Alzheimer’s disease starting as early as age 35.”
[23:08] Brief description of genetic variant, ApoE4, in the risk for cardiovascular disease and LOAD which will be covered at length in a subsequent episode here.
Omega-3 Test
Professional Supplement Store
Vitamin D Test
Omega-3 Index Plus Test
Omega-3 Test
Professional Supplement Store
Vitamin D Test
Omega-3 Index Plus Test
